Relapsing-remitting Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, Disease modifying medication, Relapsing-Remitting MS, Motivational Interviewing, Telephone Counseling
Brief summary
As many as 50% of MS patients prematurely discontinue their disease modifying medications. For this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled trial. Patients will be assigned to either 5 weekly 20 minute telephone sessions of psychotherapy or a brief education control condition. We hypothesize that patients undergoing phone therapy will be more likely to indicate they are interested in resuming taking disease modifying medications than patients given brief education and treatment as usual.
Interventions
A telephone based talk therapy discussing pros and cons of medication use in MS.
BEHAVIORALBrief Education
Give patients a pamphlet discussing pros and cons of disease modifying therapies
Sponsors
National Multiple Sclerosis Society
University of Missouri, Kansas City
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of relapsing remitting MS based on established guidelines * Previously discontinued recommended therapy * Provider recommendation for DMT re-initiation * At least 18 years of age * Access to a telephone * English speaking
Exclusion criteria
* Diagnosis other than relapsing remitting MS * Provider does not recommend DMT re-initiation * Pregnant or breastfeeding (females)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence Treatment Survey | 10 weeks after enrollment | Whether the patient indicates if he/she decided to re-initiate disease modifying therapies on a yes/no question. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adherence Treatment Survey | 10 weeks after enrollment | Whether the patient reports that he/she plans to discuss disease modifying therapies with a care provider on a yes/no question. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Motivation/Readiness Questionnaire | 10 weeks post-enrollment | Whether there is increased self-reported motivation to take disease modifying therapies on a 1-10 likert-type scale. |
Countries
United States
Outcome results
None listed